5 of Last Week's Biggest Losers

There's never a shortage of losers in the stock market. Let's take a closer look at five of this past week's biggest sinkers.

Source: Barron's.

Let's start with Plug Power. The provider of fuel cell energy solutions came down hard after being one of the prior week's hottest stocks. Plug Power soared 77% a week earlier after striking a deal with the world's largest retailer to triple the presence of its hydrogen fuel cell charging stations in its distribution centers. The profit taking took place as it completed a secondary offering at a steep discount to its market price on Tuesday. Analyst downgrades after a reasonable quarterly report later in the week didn't help. 

Gogo fell in four of the week's five trading sessions, but the sell-off intensified after posting quarterly results on Thursday morning. The results seemed solid, with the provider of in-flight Wi-Fi's deficit narrowing on a 46% surge in revenue, and its outlook for all of 2014 was in line with expectations. However, the stock had nearly tripled since bottoming out this past summer. It's not easy living up to those gains.

3D Systems posted its second consecutive week of double-digit percentage declines. A week earlier it was a Zacks Investment Research downgrade, and this week was a bad one for 3-D printing stocks in general after Barron's panned the entire tech niche. There have been kind analyst words along the way. Piper Jaffray boosted its price target a week earlier, and this time around it was Stephens using the recent pullback to upgrade the stock by keeping its $77 price target intact. The negative sentiment has clearly outweighed the two positive analyst moves.

MeetMe initially opened higher after posting quarterly results, but the social-discovery specialist eventually buckled under with the general market malaise. Mobile revenue more than doubled to make up the lion's share of MeetMe's revenue, but its overall top line only moved 12% higher for the period. 

Finally, we have Organovo skipping a beat. Organovo rose as a coattail play on 3-D printing last year, so it's not a surprise to see the volatile bio-printing specialist fall out of favor as traditional 3-D printing stocks start to slide. Organovo's lofty goal is to bio-engineer human tissue and potentially even organs that could be used to help speed up drug testing. It also updated its investor website FAQ, addressing issues including accusations of an association with a Japanese stock promoter from last year. 

Ready for a bounce
If you owned some of these losers, how about following the smart money into winners? Consider that David Gardner has proved the critics wrong time, and time, and time again with stock returns like 926%, 2,239%, and 4,371%. In fact, just recently one of his favorite stocks became a 100-bagger. And he's ready to do it again. You can uncover his scientific approach to crushing the market and his carefully chosen six picks for ultimate growth instantly, because he's making this premium report free for you today. Click here now for access.